Antibody drug conjugates (ADC) that bind to 191P4D12 proteins
View Patent ↗Antibody drug conjugates (ADC's) that bind to 191P4D12 protein and variants thereof are described herein. 191P4D12 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, the ADC's of the invention provide a therapeutic composition for the treatment of cancer.
1. An anti-191P4D12 antibody or antigen binding fragment thereof wherein the antibody or antigen binding fragment thereof comprises a heavy chain variable region comprising complementarity determining regions (CDRs) having the amino acid sequences of the heavy chain variable region CDRs set forth in SEQ ID NO:7 and a light chain variable region comprising CDRs having the amino acid sequences of the light chain variable region CDRs set forth in SEQ ID NO:8.
2. The antigen binding fragment of claim 1 , wherein the fragment is an Fab, F(ab′)2, Fv or scFv fragment.
3. The antibody of claim 1 , wherein the antibody is a fully human antibody.
4. The antibody of claim 1 , wherein the antibody is recombinantly produced.
5. An antibody drug conjugate comprising the antibody or antigen binding fragment of claim 1 conjugated to a cytotoxic agent or cytostatic agent.
6. The antibody drug conjugate of claim 5 wherein the cytotoxic agent is monomethyl auristatin E.
7. A pharmaceutical composition comprising the antibody drug conjugate of claim 5 .
8. The pharmaceutical composition of claim 7 wherein the cytotoxic agent is monomethyl auristatin E.